XT
MGX icon

XTX Topco’s Metagenomi Therapeutics MGX Stock Holding History

XTX Topco’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.4K Sell
40,582
-28,412
-41% -$44.1K ﹤0.01% 3293
2025
Q4 		$112K Buy
68,994
+53,778
+353% +$116K ﹤0.01% 2605
2025
Q3 		$36.1K Buy
+15,216
New +$30.9K ﹤0.01% 2230
2024
Q3 		– Sell
-16,244
Closed -$66.3K – 2701
2024
Q2 		$66.3K Buy
+16,244
New +$112K 0.01% 1478

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XTX Topco's MGX Position: Q1 2026 in Review

XTX Topco reduced its Metagenomi Therapeutics (MGX) stake by 41% in Q1 2026, selling an estimated $44.1K and leaving 40,582 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3293.

XTX Topco first reported a position in MGX in Q2 2024 and has held it in 4 quarters since. The position peaked at $112K in Q4 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • XTX Topco held 40,582 shares of Metagenomi Therapeutics worth $54.4K as of Q1 2026.
  • XTX Topco sold 28,412 Metagenomi Therapeutics shares in Q1 2026, an estimated $44.1K.
  • Metagenomi Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3293 holding.
  • XTX Topco first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • XTX Topco's Metagenomi Therapeutics position peaked at $112K in Q4 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.